Volltext-Downloads (blau) und Frontdoor-Views (grau)

New innovation models in pharmaceutical R&D

  • The efficiency of pharmaceutical research and development (R&D) reflected by increasing costs of R&D, long timelines, and low probabilities of technical and regulatory success decreased continuously in the past years. Today, the costs for discovering and developing a new drug are enormously high with more than USD 2 billion per new molecular entity (NME), while the average overall success of a research project to provide an NME is in the single-digit percentage rate, and the total timelines of R&D easily exceeds 10 years questioning the return on investment (ROI) of pharmaceutical R&D. As a consequence and also caused by numerous patent expirations of blockbuster drugs that increased the pressure to return to an acceptable ROI, the pharmaceutical industry addressed this challenge and the related causes and identified several actions that need to be taken to increase the output/input ratio of R&D. This book chapter will review the pipeline sizes and the R&D investments of multinational pharmaceutical companies, will describe new processes that have been implemented to increase the reach and to reduce costs of pharmaceutical R&D, and it will illustrate new innovation models that were developed to increase the R&D efficiency.

Download full text files

  • 664.pdf

Export metadata

Additional Services

Search Google Scholar


Author of HS ReutlingenSchuhmacher, Alexander
Erschienen in:Value creation in the pharmaceutical industry : the critical path to innovation
Place of publication:Weinheim
Editor:Alexander Schuhmacher
Document Type:Book chapter
Publication year:2016
Tag:R&D efficiency; innovation model; knowledge leverager; open innovation
Page Number:15
First Page:401
Last Page:415
PPN:Im Katalog der Hochschule Reutlingen ansehen
DDC classes:330 Wirtschaft
540 Chemie
Open access?:Nein
Licence (German):License Logo  In Copyright - Urheberrechtlich geschützt